Mark Gooding supports clients on market access, product commercialization, and reimbursement policy.

With a focus on oncology and other physician-administered therapies, he applies his experience to provide customers with guidance on coding, coverage, and reimbursement issues.

Prior to joining Avalere, Mark was a senior associate at Covance Market Access Services, where he supported pharmaceutical manufacturers by conducting market research with payers and providers on issues, including coverage decision-making, reimbursement and financial support program development, and alternative payment models. He also provided support through bench-marking, policy analysis, and coding application strategy. Prior to that, as a project manager and research assistant at George Washington University’s Department of Health Policy, he provided support on an array of subject areas including healthcare reform, state Medicaid policy, and early childhood development.

Mark earned an MPS in political management from the George Washington University and a BA in political science and philosophy from Wake Forest University.

Authored Content

Additional Medicare payment options available for new, high-cost technologies used in the inpatient setting.

Recent developments in the specialty pharmaceutical marketplace merit distinct attention from manufacturers.

The interaction of recently announced drug pricing reforms will have differential implications for stakeholders.